In this work, we found that the simultaneous detection of autoantibodies against GTF2B, MAPKAPK3, p53, PIM1, PKN1, SRC, STK4, and SULF1 could discriminate between control individuals and CRC patients and premalignant subjects with an AUC well above than that for CEA (the established clinical marker recommended for monitoring recurrent CRC) 90% vs 80%, and especially for the comparison between control individuals and premalignant patients 91% vs 57%. Here, SULF1 is linked to colorectal carcinoma.